Mogrify secures £12.3m in a second Series A close led by Parkwalk Advisors
The financing brings total Series A funds to $33m to advance the company cell reprogramming pipeline.
Mogrify is a biopharmaceutical company developing in vivo reprogramming therapies to address degenerative conditions. Its proprietary platforms use big data and genomics to control human cell fate.
Mogrify has secured £12.3m in a second close of its Series A financing round, bringing the total raised in the round to $33m. The investment was led by Parkwalk Advisors, with participation from Astellas Venture Management, 24Haymarket, Jonathan Milner and Darrin M Disley. The capital will be deployed to advance immuno-oncology and ophthalmology programmes toward IND-enabling studies, alongside continued platform development and exploratory work in cell reprogramming.
The financing also brings key governance updates, with Lorenz Mayr joining the board of directors as a non-executive director and Hiromichi Kimura joining as an observer. The injection of funds provides runway as the business scales its therapeutic pipeline.
From the founder
"We are delighted to see the continued support of our existing investors, as well as welcome new investors Astellas Venture Management and Dr Jonathan Milner, in support of the progression of our initial programs through to IND-enabling studies."
Darrin Disley
CEO at Mogrify
Investor perspective
"Mogrify is led by a team with proven world-class commercial and scientific expertise who have made significant progress in applying the technology to drive the speed, efficiency and maintenance of cellular reprogramming."
Alastair Kilgour
Chief Investment Officer, Parkwalk
Use of funds
- 01Fund research and development
- 02Continue product development
